In conclusion, our results show that DAAs treatment attenuated the activation of monocytes and NK cells in CHC patients during DAAs treatment, indicated by decreased levels of sCD14, sCD163, IL-12, IL-18, CXCL10, and CXCL11 and normalization of the frequency of monocytes and NK cells, but the effect of DAAs treatment on their function still needs further research. The gene discussed is CXCL11; the disease is cryohydrocytosis.